| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Coala-Life Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0001 |
| 52 Week High | €0.048 |
| 52 Week Low | €0.0001 |
| Beta | 1.02 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RBR | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | 1.9% |
| 1Y | -99.5% | -5.0% | 4.6% |
Return vs Industry: RBR underperformed the German Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: RBR underperformed the German Market which returned 4.1% over the past year.
Price Volatility
| RBR volatility | |
|---|---|
| RBR Average Weekly Movement | 5,159.1% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RBR's share price has been volatile over the past 3 months.
Volatility Over Time: RBR's weekly volatility has increased from 4057% to 5159% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 89 | Dan Pitulia | www.coalalife.com |
Coala-Life Group AB (publ) operates as a medical device company. The company develops medical innovations that enable long-term monitoring of patients in daily life, which supports diagnosis of heart and lungs and improve clinical outcomes. Its products offer healthcare providers diagnostic support by the ability to follow patient’s in everyday life.
Coala-Life Group AB (publ) Fundamentals Summary
| RBR fundamental statistics | |
|---|---|
| Market cap | €24.59m |
| Earnings (TTM) | -€12.80m |
| Revenue (TTM) | €4.25m |
0.0x
P/S Ratio0.0x
P/E RatioIs RBR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RBR income statement (TTM) | |
|---|---|
| Revenue | kr49.07m |
| Cost of Revenue | kr60.62m |
| Gross Profit | -kr11.55m |
| Other Expenses | kr136.07m |
| Earnings | -kr147.62m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | -23.55% |
| Net Profit Margin | -300.87% |
| Debt/Equity Ratio | 0% |
How did RBR perform over the long term?
See historical performance and comparison